Loyal's STAY study of LOY-002 reaches 1,000 dogs, the largest veterinary trial to date, and expands to 1,300

Loyal/LOY-002

Loyal's STAY pivotal study reached its original enrollment goal of 1,000 dogs—the largest clinical trial in veterinary history—and was expanded to 1,300 participants. The expansion increases statistical power to observe the drug's true effect and demonstrates efficacy across a broader, more diverse dog population.

• 1,000 dogs represents largest clinical trial in veterinary history, surpassing previous record of 800 dogs in vaccination study.
• Expansion to 1,300 dogs increases statistical power for LOY-002's lifespan extension claim.
• Enrollment completion at 1,300 expected within several months, advancing the pivotal study toward FDA analysis.